Vorasidenib
VORTEX (Alliance A072301)
Servier · Phase 3 · Recruiting · Enrollment 408
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| RT then TMZ + vorasidenib | newly diagnosed grade 3 IDH-mutant astrocytoma | 40 mg | ITT | placebo | n/r |
No efficacy figure is in this file for this study.